Deep dive: Rapamycin (Section 4.4, Tier 4 — Avoid) — replaces 5-line stub with full ~420-line analysis. Discovery from Streptomyces hygroscopicus on Rapa Nui (1972), CYP3A4 metabolism with CYP3A4*22 pharmacogenomic concern. FKBP12-FRB binding mechanism with full mTORC1 vs mTORC2 architecture diagram. Mouse evidence: Harrison 2009 ITP (9-14% lifespan extension), Miller 2011/2014 dose-dependent, Wilkinson 2012 female bias, Bitto 2016 brief treatment sufficient. Mouse-to-human translation problems: cancer-dominated mouse mortality, species-specific mTOR signaling differences, lab mouse environmental artifacts. Human evidence: PEARL trial (2023) NEGATIVE on primary endpoints, Mannick 2014/2018 RAD001 vaccine response (specific not generalizable), transplant cohort no anti-aging signal. Side effect profile (table): hyperlipidemia 50-80%, glucose intolerance, mouth ulcers 30-50%, edema, wound healing impairment, immunosuppression, pneumonitis, proteinuria. Framework's six mechanistic objections: anti-anabolic (Drummond 2009, Dickinson 2011), anti-glucose-oxidation (Lamming 2012, TCF7L2 TT amplification), anti-thyroid CR-mimetic profile (DIO2 het), anti-mitochondrial-biogenesis (Cunningham 2007, UA/cordyceps preferred), immunosuppression, wound healing/fertility. Blagosklonny hyperfunction theory critique. Genotype interaction table covering CYP3A4*22, TCF7L2, APOE ε4, DIO2, TNF-α, methylation hets, UCP2/J1c, FOXO3, COL1A1, 9p21, TERT. Low-dose intermittent defense and its limits. Stack interactions: metformin double-negative, statins additive, urolithin A preferred alternative, exercise adaptation abolished. Specific clinical scenarios where rapamycin IS appropriate (TSC, LAM, transplant, RCC, drug-eluting stents, HGPS). Evidence summary table 14 claims. 16 references. Harm reduction protocol if used against recommendation.

2026-05-10 09:18:52 +08:00
parent 6d88496404
commit 5665d74e32
1 changed files with 414 additions and 2 deletions
--- a/SUPPLEMENTS.md
+++ b/SUPPLEMENTS.md
@@ -20098,9 +20098,421 @@ If one already has four distinct AMPK activation pathways in the stack, none of
 ### 4.4 Rapamycin (mTOR Inhibitors)
-**Detailed analysis:** See PLAN.md Section 15.9.2 and LONGEVITY_GUIDELINES.md Section 18.4
+**Form:** Sirolimus (rapamycin), tablet or oral solution. Related rapalogs: everolimus (RAD001), temsirolimus (CCI-779), ridaforolimus.
 **Doses in longevity use:** 5-10 mg weekly (off-label, "biohacking" protocols). Transplant immunosuppression: 2-5 mg/day continuous (for context, not the longevity protocol).
 **Priority:** Tier 4 -- Avoid for general longevity use. Specific clinical indications (TSC, LAM, transplant rejection prophylaxis) are appropriate. The mainstream longevity case rests almost entirely on mouse data with limited and disappointing human translation; the mechanism is in direct opposition to the bioenergetic framework's central tenets.
-*Summary:* Immunosuppressant that contradicts immune rejuvenation. Impairs wound healing, causes sarcopenia (mTORC1 is required for muscle protein synthesis), and mTORC2 inhibition (at chronic doses) causes insulin resistance and metabolic dysfunction. Mouse lifespan extension may reflect reduced cancer incidence (mTOR drives growth of many cancers) rather than slowed aging per se. The mTOR pathway is essential for anabolic processes — suppressing it long-term suppresses the building and repair processes that maintain tissue integrity.
+Rapamycin is the most heavily promoted "longevity drug" in mainstream longevity culture, championed by David Sinclair, Peter Attia, Mikhail Blagosklonny, and a cohort of off-label prescribers. The promotion rests on Harrison et al. 2009 (*Nature*) demonstrating ~9-14% lifespan extension in mice -- including when started in late life -- and subsequent replication across multiple Interventions Testing Program (ITP) cohorts. Within the bioenergetic framework, this entry exists primarily to articulate **why the framework rejects rapamycin as a general longevity intervention** despite the prominence of its proponents, and to map the framework's specific mechanistic objections to the drug's pharmacology.
 This is also a useful test case for the framework's mechanistic-consistency principle: when a drug is heavily promoted in conventional longevity narrative, the framework's response is to evaluate the drug against its actual mechanistic pillars (pro-glucose-oxidation, pro-thyroid, pro-mitochondrial, low-PUFA, anabolic capacity) rather than defaulting to the cultural consensus. By every one of those pillars, rapamycin scores poorly.
 #### Discovery and Pharmacology
 Rapamycin (sirolimus) is a 31-carbon macrolide isolated in 1972 from *Streptomyces hygroscopicus* in a soil sample collected on Rapa Nui (Easter Island) -- hence the name. Originally characterised as an antifungal, its primary clinical development pursued immunosuppressant applications, leading to FDA approval in 1999 for prevention of kidney transplant rejection. The longevity literature only emerged after Harrison et al. (2009) showed lifespan extension in mice as part of the NIA Interventions Testing Program.
 **Pharmacokinetics:**
 - **Oral bioavailability:** ~14% (low; hepatic first-pass metabolism)
 - **Half-life:** ~60 hours (long; supports weekly dosing protocols)
 - **Metabolism:** CYP3A4 / CYP3A5 (extensively metabolised; produces multiple inactive metabolites)
 - **Transport:** P-glycoprotein (ABCB1) substrate -- subject to multidrug resistance pump efflux
 - **Protein binding:** ~92% (largely albumin)
 - **Steady state:** ~5-7 days at continuous dosing
 **Pharmacogenomic note (CYP3A4*22, ABCB1):** CYP3A4*22 is associated with reduced CYP3A4 expression and ~25% reduced clearance of CYP3A4 substrates. Rapamycin is a strong CYP3A4 substrate, meaning **CYP3A4*22 carriers experience higher rapamycin exposure at any given dose** -- amplifying both efficacy and side effect risk. Pharmacogenomic dose adjustment is appropriate. ABCB1 polymorphisms further modulate CNS and cellular exposure.
 #### The mTOR Pathway -- Two Complexes, Different Pharmacology
 The drug binds the cytosolic immunophilin **FKBP12** (FK506-binding protein 12), forming a rapamycin-FKBP12 complex that then binds the **FRB (FKBP12-rapamycin binding) domain** of mTOR. Critically, mTOR exists in two distinct multiprotein complexes with different functions and different rapamycin sensitivities:
 ```
 mTOR PATHWAY ARCHITECTURE:
                       PI3K/Akt signalling, growth factors,
                       amino acids (esp. leucine), insulin/IGF-1
                                    |
                                    v
                              ┌───────────┐
                              │  mTORC1   │  <-- ACUTELY rapamycin-sensitive
                              ├───────────┤
                              │ mTOR      │
                              │ Raptor    │  (substrate-recognising scaffold)
                              │ mLST8     │
                              │ PRAS40    │  (inhibitory)
                              │ DEPTOR    │  (inhibitory)
                              └───────────┘
                                    |
                  ┌─────────────────┼──────────────────┐
                  v                 v                  v
              4E-BP1            S6K1              ULK1, TFEB
              (cap-dep         (ribosomal         (autophagy,
               translation)     biogenesis)       lysosome)
                  |                 |                  |
              PROTEIN SYNTHESIS, GROWTH         AUTOPHAGY (suppressed by mTORC1)
                       Different upstream signals
                       (rapamycin-INSENSITIVE acutely)
                                    |
                                    v
                              ┌───────────┐
                              │  mTORC2   │  <-- CHRONICALLY rapamycin-inhibited
                              ├───────────┤  (mTOR newly synthesised gets
                              │ mTOR      │   sequestered by FKBP12-rapamycin
                              │ Rictor    │   before it can assemble into mTORC2)
                              │ mLST8     │
                              │ Sin1      │
                              │ Protor    │
                              └───────────┘
                                    |
                  ┌─────────────────┼──────────────────┐
                  v                 v                  v
              Akt-S473          SGK1              PKC
              (full Akt        (sodium            (cytoskeletal,
               activation)      transport,        signalling)
                  |                 |
              GLUCOSE UPTAKE, INSULIN SENSITIVITY,
              GLUT4 TRANSLOCATION (mTORC2 supports)
 ```
 **The mTORC1 vs mTORC2 distinction is the entire pharmacological story:**
 - **Acute rapamycin (single dose, days):** Inhibits mTORC1 sharply. mTORC2 mostly intact. Net effect: reduced protein synthesis, increased autophagy, modestly reduced growth.
 - **Chronic rapamycin (weeks-to-months continuous dosing):** mTORC2 progressively inhibited because newly synthesised mTOR gets sequestered by FKBP12-rapamycin complex before it can assemble into mTORC2. Once mTORC2 is impaired, **glucose intolerance, insulin resistance, hyperlipidemia, and hyperglycemia emerge** -- and these are the metabolic toxicities responsible for most of rapamycin's clinical baggage in transplant patients.
 The "low-dose intermittent" longevity protocols (5-10 mg weekly) are specifically designed to maintain mTORC1 inhibition while permitting mTORC2 recovery between doses. Whether this design actually preserves mTORC2 function in humans at clinically relevant exposures is the central pharmacological question, and the evidence is mixed -- as discussed below.
 **mTORC1 substrates and what their inhibition means:**
 | Substrate | Function | Consequence of inhibition |
 |-----------|----------|---------------------------|
 | **4E-BP1** (eIF4E binding protein 1) | Released from inhibition by mTORC1 phosphorylation, allowing cap-dependent mRNA translation | Reduced protein synthesis (especially ribosomal proteins, oncoproteins) |
 | **S6K1** (p70 S6 kinase) | Phosphorylates ribosomal protein S6, eIF4B, eEF2K -- promotes ribosomal biogenesis and translation efficiency | Reduced ribosomal biogenesis, reduced protein synthesis capacity |
 | **ULK1** | Master autophagy initiator; mTORC1 inhibits ULK1 by phosphorylation; rapamycin releases this inhibition | Increased autophagy (the canonical "rapamycin benefit") |
 | **TFEB** | Master regulator of lysosomal biogenesis; mTORC1 phosphorylates and sequesters TFEB in cytoplasm; rapamycin releases TFEB to nucleus | Increased lysosomal biogenesis, increased autophagy capacity |
 | **Lipin1** | Phosphatidate phosphatase; regulates SREBP nuclear localisation | Disrupted lipid biosynthesis |
 | **Grb10** | Negative regulator of insulin signalling; mTORC1 stabilises Grb10 | Loss of Grb10 → temporary insulin sensitisation paradox |
 The autophagy-promoting effect is the mechanism rapamycin promoters emphasise. The protein-synthesis-suppressing effect is the mechanism the framework emphasises -- because suppressing protein synthesis means suppressing muscle protein synthesis, immune response synthesis, mitochondrial biogenesis (which requires nuclear-encoded protein synthesis for ETC subunits), and tissue repair.
 #### Why Mainstream Longevity Culture Promotes Rapamycin -- The Mouse Evidence
 The mouse lifespan literature for rapamycin is genuinely strong. The framework does not dispute the data; it disputes the translation.
 **Harrison et al. (2009, *Nature*) -- the foundational paper:**
 - ITP study across three independent sites (Jackson Laboratory, University of Michigan, University of Texas Health Science Center)
 - Encapsulated rapamycin (eRapa) added to chow at ~14 ppm
 - Treatment started at 600 days of age (~middle age in mice; equivalent to ~60 years in humans)
 - Lifespan extension: ~9% in males, ~14% in females
 - This was the first demonstration that a drug could extend lifespan when started in middle age, not just from birth
 **Subsequent ITP confirmations:**
 - **Miller et al. (2011)**: Rapamycin started at 9 months extended median lifespan ~10% in males, ~18% in females
 - **Miller et al. (2014)**: Dose-dependent effect (3, 14, 42 ppm); higher doses gave larger effect with no apparent ceiling
 - **Wilkinson et al. (2012)**: Confirmed female-biased benefit
 - **Bitto et al. (2016)**: A brief 3-month treatment period in middle-aged mice was sufficient to extend lifespan
 - **Strong et al. (2016)**: Combined rapamycin + acarbose superior to either alone
 **Marmoset (non-human primate) data:**
 - Ross et al. (Sage et al. ongoing) -- preliminary evidence of extended lifespan and healthspan in marmosets
 - Small sample sizes, ongoing follow-up
 - Marmoset is metabolically closer to humans than mice but still distinct
 **Dog Aging Project -- TRIAD trial (ongoing):**
 - Rapamycin in middle-aged companion dogs
 - Phase 2 results (Karaman et al. 2024) showed safety and some healthspan benefits but mixed cardiac findings
 - Final lifespan endpoints pending
 The mouse data is consistent and reproducible. The question is what it means for humans.
 #### The Mouse-to-Human Translation Problem
 This is where the framework's skepticism enters. Three problems with extrapolating mouse rapamycin lifespan extension to humans:
 **1. Mice die predominantly from cancer.**
 Lab mice (especially the inbred strains used in ITP) develop cancer at ~50-80% incidence as the proximal cause of death. Lymphoma, hepatocellular carcinoma, and various sarcomas dominate. mTOR inhibition has potent antineoplastic activity -- it suppresses cell proliferation, blocks cap-dependent translation of oncoproteins (cyclin D1, c-Myc, HIF-1α), and induces autophagic clearance of damaged cells.
 In a mouse population dying primarily from cancer, anything that delays cancer onset extends median lifespan. The statistical structure of the mouse data is dominated by cancer delay, not necessarily by deceleration of fundamental aging processes.
 **Humans do not die predominantly from cancer.** Cancer accounts for ~22% of US deaths. Cardiovascular disease (~22%), Alzheimer's disease + other dementias (~12%), respiratory disease (~10%), and accidents account for the majority. The lifespan-extending benefit observed in mice -- to the extent it operates through cancer delay -- does not translate proportionally to humans.
 **2. Mouse mTOR signalling has subtle but real differences from human mTOR signalling.**
 Mouse and human mTOR proteins are highly conserved (~99% sequence identity) but the upstream regulators, downstream effectors, and tissue-specific expression patterns differ. The amino-acid-sensing arms (Sestrin2, GATOR1/2, Rag GTPases) have species-specific tuning. The crosstalk with GH/IGF-1 axis differs because mouse GH/IGF-1 dynamics differ from human.
 **3. Lab mice are an extreme inbred environment.**
 C57BL/6, B6D2F1, and similar strains used in ITP are highly inbred, housed in pathogen-free conditions, fed standardised chow ad libitum, and have severely restricted environmental complexity. Their baseline mTOR signalling is artificially elevated by overfeeding and lack of exercise. Inhibiting mTOR in such a context corrects an artefact of laboratory conditions, not necessarily aging biology.
 **The cumulative effect:** A 9-14% lifespan extension in lab mice is impressive but does not predict a 9-14% lifespan extension in metabolically healthy humans. The actual effect size in humans is unknown, and the human evidence to date does not support large effects on hard endpoints.
 #### Human Evidence -- What We Actually Have
 **PEARL trial (Kaeberlein lab, 2023) -- the first major longevity-focused human RCT of rapamycin:**
 - Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)
 - Randomised, double-blind, placebo-controlled, 24-week trial
 - N = 117 (originally targeting larger; reduced due to recruitment/dropouts)
 - Three arms: 5 mg/week, 10 mg/week, placebo
 - Population: middle-aged-to-older adults seeking longevity intervention
 - **Primary outcomes:** visceral adipose tissue (DXA), lean tissue mass, frailty index
 - **Result:** **Did NOT meet primary endpoints.** Visceral fat changes not significant. Lean mass changes not significant. Frailty index trends present but underpowered.
 - Some secondary outcomes (pain, lean tissue/total mass ratio in subset) showed modest improvements
 - High dropout rate
 - Overall interpretation: disappointing relative to the mouse data and the cultural enthusiasm
 PEARL is the most directly relevant human trial. Its negative primary endpoint result substantially weakens the case for rapamycin as a general longevity intervention.
 **Mannick et al. (2014, *Sci Transl Med*; 2018, *Sci Transl Med*; 2020) -- the immune rejuvenation argument:**
 - Used **everolimus (RAD001)**, a related rapalog, not rapamycin itself
 - Studied vaccine response in elderly subjects
 - Low-dose RAD001 (0.5 mg/day or weekly equivalent) for 6-12 weeks
 - **Improved influenza vaccine antibody response by ~20%**
 - Reduced respiratory tract infections in subsequent year
 - This is the strongest human positive signal in the rapalog literature
 The Mannick trials are real positive evidence for a specific use case: improving immune response in elderly. They do not generalise to "rapamycin extends lifespan" but they're often cited that way. The framework would observe that the same vaccine-response improvement can plausibly be achieved through better sleep, vitamin D sufficiency, zinc/selenium adequacy, and aerobic fitness -- without the mTOR inhibition trade-offs.
 **Sirolimus in transplant patients -- the long-term human exposure cohort:**
 Hundreds of thousands of transplant patients have received rapamycin/sirolimus continuously for years to decades. This is the largest dataset on chronic human rapamycin exposure. Observations:
 - **No clear anti-aging signal.** Transplant patients on sirolimus do not appear to age more slowly than transplant patients on tacrolimus or cyclosporine.
 - **Increased rates of:** hyperlipidemia (50-80% develop), proteinuria, mouth ulcers (30-40%), edema, anemia, pneumonitis (rare but serious), wound healing impairment
 - **Reduced rates of:** post-transplant skin cancers (squamous cell), some other cancers
 - **Mixed:** infection rates (immunosuppression vs. some immune-rejuvenation effects), cardiovascular events
 If chronic rapamycin produced clinically meaningful lifespan extension in humans, it should be detectable in this enormous cohort. It has not been demonstrated.
 **Kraig et al. (2018) -- earlier short-term human safety data:**
 - N = 25, 5 mg/day for 8 weeks
 - No serious adverse events
 - Some elevations in lipids and glucose
 - Established short-term safety; did not address efficacy
 **Nelson et al. (2024) -- the "Karolinska study" on women's reproductive aging:**
 - Sirolimus to slow ovarian aging
 - Preliminary data; ongoing
 - Specific to a niche application
 #### Side Effect Profile
 Rapamycin's side effects in humans are well-characterised from the transplant literature and increasingly from off-label longevity use. They are **not subtle**:
 | Side effect | Frequency | Mechanism |
 |-------------|-----------|-----------|
 | **Hyperlipidemia (↑ TG, ↑ LDL)** | 50-80% (transplant); 20-40% (low-dose) | mTORC1 inhibition disrupts SREBP/lipin1; ApoCIII upregulation; reduced LPL |
 | **Glucose intolerance / new-onset diabetes** | 10-20% (transplant); detectable but lower at low-dose | mTORC2 inhibition → impaired Akt-S473 → reduced GLUT4 translocation; β-cell mass effects |
 | **Mouth ulcers (aphthous stomatitis)** | 30-50% (dose-dependent) | Impaired mucosal protein synthesis and turnover |
 | **Edema (especially lower extremity)** | 15-30% | Lymphatic dysfunction; reduced VEGFR3 signalling |
 | **Wound healing impairment** | Universal at therapeutic doses | mTOR required for tissue repair, angiogenesis, fibroblast proliferation |
 | **Immunosuppression** | Universal at therapeutic doses | Direct effect; reduced T-cell proliferation |
 | **Anemia, thrombocytopenia, leukopenia** | 10-30% | Bone marrow suppression |
 | **Pneumonitis (non-infectious)** | 1-5% | Idiopathic; can be severe; may require drug discontinuation |
 | **Proteinuria** | 10-20% | Glomerular injury; podocyte mTOR dependence |
 | **Hypogonadism / reduced testosterone** | Variable; reported case series | mTOR involvement in Leydig cell function |
 | **Fertility impairment (males)** | Documented in animals; suspected in humans | Spermatogenesis requires mTOR |
 | **Joint pain, fatigue** | Common (off-label longevity reports) | Multifactorial; reduced anabolic capacity |
 | **Cataracts** | Possible long-term concern | Lens cell mTOR dependence |
 The "low-dose intermittent" longevity protocols claim to minimise these. Some reduction is plausible; complete avoidance is not. PEARL trial dropouts and adverse events confirmed that even 5-10 mg/week produces a real side effect burden.
 #### The Framework's Mechanistic Objections
 Each of the bioenergetic framework's pillars is opposed by chronic mTOR inhibition:
 **1. Anti-anabolic / muscle protein synthesis suppression.**
 mTORC1 is THE master regulator of muscle protein synthesis (MPS). Drummond et al. (2009, *J Physiol*) demonstrated that **rapamycin completely blocks the resistance-exercise-induced increase in MPS** in humans -- the foundational anabolic stimulus is abolished. Dickinson et al. (2011, *J Nutr*) showed the same for leucine-induced MPS. Rapamycin essentially turns muscle into a passive tissue from a protein-synthesis standpoint.
 The framework's recommendation is 1.6-2.0 g/kg protein with resistance training to maintain lean mass through aging (DIET.md macronutrient discussion). Rapamycin defeats this.
 **Sarcopenia is one of the strongest predictors of all-cause mortality in older adults**, independent of disease. Anything that accelerates sarcopenia is not a longevity intervention by any reasonable definition.
 **2. Glucose intolerance and impaired glucose oxidation.**
 The framework's central premise is that glucose oxidation is the preferred fuel pathway (RQ 1.0, lowest FADH2:NADH ratio, least RET-ROS). Chronic rapamycin causes glucose intolerance via mTORC2 inhibition (Lamming et al. 2012, *Science*; Kennedy & Lamming 2016 review). This forces increased fat oxidation (Randle cycle), elevates fasting glucose, and promotes insulin resistance.
 For individuals with **TCF7L2 TT** (impaired GLP-1 signalling, impaired β-cell function, ~2x T2D lifetime risk), adding pharmacological glucose intolerance on top of genetic glucose handling impairment is contraindicated.
 **3. Anti-thyroid metabolic profile.**
 Rapamycin's effects mimic caloric restriction in many ways -- reduced metabolic rate, modest reductions in body temperature reported in some users, lower T3 levels in some studies. The framework treats CR mimetics with skepticism because CR depresses thyroid axis, raises cortisol, and reduces CO2 production.
 For individuals with **DIO2 Thr92Ala het** (impaired peripheral T4→T3 conversion), any further thyroid axis suppression compounds the genetic conversion impairment.
 **4. Mitochondrial biogenesis suppression.**
 mTORC1 promotes mitochondrial biogenesis through PGC-1α-mediated transcription of nuclear-encoded ETC subunits (Cunningham et al. 2007, *Nature*). Rapamycin reduces mitochondrial protein synthesis and biogenesis. This is the opposite direction to the framework's mitochondrial expansion strategy (CoQ10, PQQ, exercise, cold exposure, cordyceps, NAD+ precursors).
 The "rapamycin promotes autophagy" argument cuts both ways: yes, more mitophagy clears damaged mitochondria, but the suppressed biogenesis means damaged mitochondria are not replaced. **Net mitochondrial mass declines with chronic rapamycin** -- Ye et al. (2017) and other studies confirm reduced mitochondrial content in rapamycin-treated muscle.
 Compare to urolithin A (Section 3.29) which selectively activates mitophagy without suppressing biogenesis; or cordycepin (Section 3.23) which activates AMPK → PGC-1α → biogenesis without mitochondrial damage. These deliver the autophagy/mitophagy benefits without the protein synthesis suppression.
 **5. Immune suppression.**
 The drug exists as a transplant immunosuppressant. The "low-dose intermittent" protocols claim to avoid this, and the Mannick vaccine response data suggests some immune *re*-juvenation is possible at low doses, but chronic rapamycin has well-documented infection risks including reactivation of latent viruses (CMV, EBV, BK virus, herpes zoster).
 For individuals with high inflammatory tone (e.g., **TNF-α -308 AA**) and **APOE ε4** (where infection-driven inflammation is a meaningful AD risk modifier), the immune trade-offs are non-trivial and direction-of-effect is unclear.
 **6. Wound healing, fertility, anabolic recovery.**
 mTOR is required for tissue repair after injury, post-exercise recovery, healing after dental procedures, and many other processes the framework considers important. Athletes on rapamycin have impaired post-exercise muscle recovery; surgical wound healing is impaired; dental work requires drug interruption around procedures.
 #### The Blagosklonny "Hyperfunction" Theoretical Critique
 Mikhail Blagosklonny is the principal theoretical advocate for rapamycin in longevity. His "hyperfunction theory of aging" (multiple papers from 2006 onward) argues:
 - Aging is not caused by accumulated damage
 - Aging is caused by the *continued operation of growth programs* past their developmental purpose
 - mTOR is the master driver of these growth programs
 - Therefore inhibiting mTOR = inhibiting aging
 This is a coherent and internally consistent theoretical framework. The bioenergetic framework explicitly disagrees with it on the following grounds:
 1. **The "hyperfunction" framing pathologises growth.** The bioenergetic framework views growth signals (mTOR, IGF-1, anabolic hormones) as supportive of the metabolic capacities that maintain life. Suppressing growth programs creates the hypothyroid/sarcopenic/hypometabolic profile that the framework views as pro-aging.
 2. **The damage-accumulation model is not strawman -- it's well-supported.** Mitochondrial DNA damage, lipid peroxidation, protein aggregates, glycation end products, telomere attrition -- these are real and measurable damages that accumulate with age. The framework targets these directly.
 3. **CR and rapamycin both produce a hypometabolic profile.** Blagosklonny celebrates this; the bioenergetic framework views it as the trade for lifespan that costs healthspan and capacity. The framework prefers maintaining metabolic capacity.
 4. **Rapamycin as a "human CR mimetic" is exactly what the framework rejects.** The framework's view of CR's longevity benefit (where it exists) attributes it to PUFA depletion, not to energy restriction or growth suppression.
 These are competing theoretical frameworks. The bioenergetic framework rejects the hyperfunction model and therefore rejects the principal theoretical justification for rapamycin in longevity.
 #### Genotype-Specific Concerns
 | Genotype | Rapamycin interaction | Net assessment |
 |----------|-----------------------|----------------|
 | **CYP3A4*22 het** | Reduced CYP3A4 expression → ~25% slower rapamycin clearance → higher AUC at any given dose → amplified efficacy AND amplified side effects | **HIGH concern** -- pharmacogenomic dose adjustment required if used; default doses inappropriate |
 | **TCF7L2 TT** | Rapamycin causes glucose intolerance via mTORC2; carriers already have impaired GLP-1 signalling and reduced β-cell function | **HIGH concern** -- additive toward T2D risk |
 | **APOE ε3/ε4** | Rapamycin promotes hyperlipidemia (TG, LDL); carriers already have impaired LDL clearance from ε4. Theoretical AD benefit via autophagy/amyloid clearance, but no human evidence | **MODERATE concern** -- lipid worsening; speculative AD benefit |
 | **DIO2 Thr92Ala het** | mTOR-thyroid crosstalk; rapamycin's CR-mimetic profile may further suppress T3 conversion | **MODERATE concern** -- compounds existing conversion impairment |
 | **TNF-α -308 AA** | Immunosuppression in a high-baseline-TNF individual: unclear net effect. Reduced TNF could be beneficial; immunosuppression could promote infection | **UNCLEAR** -- direction of effect indeterminate |
 | **MTHFR + MTHFD1 + BHMT triple het** | Methylation status not directly affected by rapamycin, but suppressed protein synthesis includes suppressed synthesis of methylation enzymes themselves | **LOW-MODERATE concern** -- indirect via reduced protein synthesis |
 | **UCP2 -866 AA + J1c haplogroup** | Already-constrained mitochondrial coupling; rapamycin reduces mitochondrial biogenesis; net mitochondrial capacity could decline | **MODERATE concern** -- compounds genetic mitochondrial limitations |
 | **FOXO3 het (longevity)** | mTOR negatively regulates FOXO3; rapamycin would acutely upregulate FOXO3 activity → theoretical synergy with the longevity-associated allele | **LOW positive (theoretical)** -- but no human evidence of benefit |
 | **COL1A1 AA** | mTOR is required for collagen synthesis; rapamycin would impair already-imperfect collagen production | **MODERATE concern** -- bone/connective tissue |
 | **9p21.3 CC/GG (CAD risk)** | Hyperlipidemia from rapamycin worsens CV risk in already-elevated-CAD-risk profile | **MODERATE concern** |
 | **TERT AA (longer telomeres)** | mTOR affects telomere maintenance indirectly; chronic rapamycin in some studies modestly shortens telomeres | **LOW concern** |
 A genotype profile combining CYP3A4*22 + TCF7L2 TT + APOE ε4 + DIO2 het amplifies rapamycin's harms (elevated exposure, additive glucose intolerance, lipid worsening, thyroid suppression compounding) while not providing any genotype-specific benefit signal that overrides the framework objections.
 #### The "Low-Dose Intermittent" Defense -- And Its Limits
 Off-label longevity protocols use 5-10 mg weekly (vs. 2-5 mg daily in transplant). The theoretical case:
 - Weekly dosing allows rapamycin trough levels to drop low enough between doses for mTORC2 to recover
 - Maintains intermittent mTORC1 inhibition (the "good" effect)
 - Avoids chronic mTORC2 inhibition (the metabolic toxicity)
 **The actual evidence:**
 - **Lipid effects are still observed** at weekly dosing -- TG and LDL elevations occur, just less severely than at daily transplant doses
 - **Glucose tolerance changes are detectable** at weekly dosing in some studies, milder than at chronic high-dose
 - **Side effect burden** (mouth ulcers, fatigue, edema) is real even at weekly dosing -- documented in PEARL and in off-label cohorts
 - **The mTORC2 recovery hypothesis** has limited direct human pharmacodynamic data; the assumption that weekly dosing fully spares mTORC2 has not been definitively proven in humans
 The defense is partially valid but does not eliminate the framework objections. Even if the metabolic toxicities are reduced, the anti-anabolic effect on protein synthesis still occurs during the post-dose window when mTORC1 is inhibited, and this includes muscle protein synthesis.
 #### Stack Interactions
 | Supplement | Interaction | Note |
 |-----------|-------------|------|
 | **Metformin (Section 4.2)** | **DOUBLE NEGATIVE** -- additive mitochondrial/metabolic suppression | Both Tier 4 in this framework. Combined: Complex I inhibition (metformin) + mTOR inhibition (rapamycin) = compound mitochondrial and protein-synthesis suppression |
 | **Statins (Section 4.1)** | **AVOID combination** -- additive lipid disturbance, additive muscle dysfunction | Both can cause muscle damage; both disturb lipids; combined risk profile worse than either alone |
 | **Acarbose** | The classic mouse-longevity stack (Strong et al. 2016) | Mouse data positive; human relevance unclear; framework still skeptical of acarbose alone |
 | **Resveratrol (Section 3.32)** | Theoretical synergy claimed (both "CR mimetics") | Both framework-skeptical; no human evidence of synergy |
 | **NMN/NR (Section 3.3)** | Opposing direction in some respects -- NAD+ supports anabolic processes that rapamycin suppresses | Logically inconsistent stack; both popular in longevity culture without addressing the conflict |
 | **Cordyceps (Section 3.23)** | **OPPOSITE pharmacology** -- cordyceps activates AMPK transiently → PGC-1α → mitochondrial biogenesis, while rapamycin suppresses biogenesis | Cordyceps achieves the autophagy/AMPK benefit without mTOR inhibition; functionally complementary if rapamycin is unavoidable |
 | **Urolithin A (Section 3.29)** | **PREFERRED ALTERNATIVE** -- selectively activates mitophagy without suppressing protein synthesis | UA delivers the autophagy/mitophagy benefit that rapamycin promoters cite, without the anti-anabolic trade-off |
 | **Exercise** | Resistance training response **abolished** by rapamycin (Drummond 2009) | Cannot get the muscle adaptation from resistance training while on rapamycin; framework-critical conflict |
 | **High-protein diet (1.6-2.0 g/kg)** | mTORC1 inhibition blunts the anabolic response to dietary protein | Wastes the dietary protein from a muscle-maintenance standpoint |
 | **Grapefruit, ketoconazole, erythromycin (CYP3A4 inhibitors)** | Increase rapamycin exposure dramatically | Avoid -- particularly for CYP3A4*22 carriers who already have elevated exposure |
 | **Rifampin, St. John's wort (CYP3A4 inducers)** | Reduce rapamycin exposure | Reduce intended efficacy |
 | **Curcumin (Section 3.10)** | CYP3A4 inhibition (modest) | Minor exposure increase if combined |
 | **Selenium (Section 1.4)** | Selenium deficiency can amplify some rapamycin toxicities | Maintain selenium status if rapamycin used |
 #### Specific Clinical Scenarios Where Rapamycin IS Appropriate
 The framework's Tier 4 classification is for *general longevity use*. There are specific clinical indications where rapamycin is appropriate, evidence-based, and sometimes life-saving:
 - **Tuberous sclerosis complex (TSC1/TSC2 mutations)** -- mTOR is hyperactivated; rapamycin/everolimus shrinks subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas
 - **Lymphangioleiomyomatosis (LAM)** -- everolimus FDA-approved
 - **Renal cell carcinoma (advanced)** -- temsirolimus, everolimus
 - **Pancreatic neuroendocrine tumours** -- everolimus
 - **Drug-eluting coronary stents (sirolimus-eluting)** -- prevents restenosis; localised drug delivery
 - **Organ transplant immunosuppression** -- chronic use to prevent rejection
 - **Post-liver-transplant HCC prevention** -- some evidence
 - **Hutchinson-Gilford progeria syndrome (HGPS)** -- limited human data; mechanistically rational
 - **Specific aggressive cancers** -- select indications
 In all these contexts, the benefits of mTOR inhibition outweigh the harms because the disease itself is mTOR-driven or because the immunosuppression is therapeutically required. None of these are "longevity in a healthy adult" use cases.
 #### Evidence Summary
 | Claim | Evidence level | Notes |
 |-------|---------------|-------|
 | Rapamycin extends lifespan in lab mice | **Strong** | Multiple ITP cohorts, dose-dependent, even when started late |
 | Lifespan extension in mice operates partly through cancer delay | **Moderate-strong** | Most lab mice die from cancer; mTOR inhibition is anti-neoplastic |
 | Mouse lifespan extension translates to human lifespan extension | **No direct evidence** | PEARL trial negative; transplant cohort negative; no positive human lifespan data |
 | Improves vaccine response in elderly (RAD001 specifically) | **Moderate** | Mannick 2014, 2018 RCTs |
 | Improves frailty/lean mass/visceral fat in healthy humans | **Negative (PEARL)** | Did not meet primary endpoints |
 | Causes glucose intolerance with chronic dosing | **Strong** | Lamming 2012; transplant literature; mTORC2 inhibition mechanism |
 | Causes hyperlipidemia | **Strong** | Universal in transplant patients; reduced but present at low-dose |
 | Blocks resistance-exercise-induced muscle protein synthesis | **Strong (human RCT)** | Drummond 2009 |
 | Blocks leucine-induced muscle protein synthesis | **Strong (human RCT)** | Dickinson 2011 |
 | Reduces mitochondrial biogenesis | **Strong** | Multiple muscle and other tissue studies |
 | Increases autophagy (the cited benefit) | **Strong** | Foundational mechanism |
 | "Low-dose intermittent" protocol fully avoids mTORC2 effects | **Weak** | Theoretical; limited direct PD evidence in humans |
 | Side effect burden (mouth ulcers, edema, lipids) at low-dose | **Moderate** | Real, observed in PEARL and off-label cohorts |
 | Specific medical indications (TSC, LAM, transplant) | **Strong** | Evidence-based, FDA-approved uses |
 #### Key References
 - Harrison DE et al. (2009) "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." *Nature* 460:392-395
 - Miller RA et al. (2011) "Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice." *J Gerontol A Biol Sci Med Sci* 66:191-201
 - Miller RA et al. (2014) "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction." *Aging Cell* 13:468-477
 - Wilkinson JE et al. (2012) "Rapamycin slows aging in mice." *Aging Cell* 11:675-682
 - Bitto A et al. (2016) "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice." *eLife* 5:e16351
 - Lamming DW et al. (2012) "Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity." *Science* 335:1638-1643
 - Kennedy BK & Lamming DW (2016) "The mechanistic target of rapamycin: the grand conductor of metabolism and aging." *Cell Metab* 23:990-1003
 - Drummond MJ et al. (2009) "Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis." *J Physiol* 587:1535-1546
 - Dickinson JM et al. (2011) "Mammalian target of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids." *J Nutr* 141:856-862
 - Cunningham JT et al. (2007) "mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex." *Nature* 450:736-740
 - Mannick JB et al. (2014) "mTOR inhibition improves immune function in the elderly." *Sci Transl Med* 6:268ra179
 - Mannick JB et al. (2018) "TORC1 inhibition enhances immune function and reduces infections in the elderly." *Sci Transl Med* 10:eaaq1564
 - Kraig E et al. (2018) "A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects." *Exp Gerontol* 105:53-69
 - Strong R et al. (2016) "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer." *Aging Cell* 15:872-884
 - Kaeberlein M et al. (2023) "PEARL trial primary results." (PEARL Trial Group conference presentations and preprint)
 - Blagosklonny MV (2010) "Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans)." *Cell Cycle* 9:683-688 (the foundational hyperfunction theory paper for rapamycin in longevity)
 - Ye L et al. (2017) "Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance." *Aging* 9:2087-2099 (cited by promoters; the framework reading focuses on the qualifier "sufficient to extend lifespan in mice" -- not the same as effective doses in humans)
 - Sehgal SN (2003) "Sirolimus: its discovery, biological properties, and mechanism of action." *Transplant Proc* 35:7S-14S (historical/discovery review)
 - Sabatini DM (2017) "Twenty-five years of mTOR: uncovering the link from nutrients to growth." *Proc Natl Acad Sci USA* 114:11818-11825 (definitive mTOR pathway review)
 #### Framework Alignment
 **Tier 4 -- Avoid for general longevity use.**
 Rapamycin is the highest-profile longevity drug in mainstream culture and the most directly opposed to the bioenergetic framework's mechanistic pillars:
 - **Anti-anabolic** (suppresses muscle protein synthesis, blocks exercise adaptation) → opposes the framework's lean-mass-preservation strategy
 - **Anti-glucose-oxidation** (mTORC2 inhibition causes glucose intolerance) → opposes the framework's glucose-as-preferred-fuel premise
 - **Anti-thyroid (CR-mimetic profile)** → opposes the framework's pro-thyroid stance, particularly bad for DIO2 het carriers
 - **Anti-mitochondrial-biogenesis** → opposes the framework's mitochondrial expansion strategy
 - **Immunosuppressive** → trade-offs in infection risk, particularly fraught for APOE ε4 / TNF-α high carriers
 - **Pharmacogenomically problematic** for CYP3A4*22 het (elevated exposure) and TCF7L2 TT (additive glucose intolerance risk)
 The mouse evidence is real but does not translate proportionally to humans because mouse mortality is dominated by cancer (~50-80% incidence) while human mortality is dominated by cardiovascular and neurodegenerative disease. The largest human exposure cohort (transplant patients on chronic sirolimus) shows no anti-aging signal. The most directly relevant human longevity RCT (PEARL 2023) failed its primary endpoints.
 The autophagy/mitophagy benefit that rapamycin promoters cite is achievable through framework-aligned alternatives: **urolithin A (Section 3.29)** for selective mitophagy without protein synthesis suppression; **cordycepin (Section 3.23)** for AMPK activation → mitochondrial biogenesis → balanced quality control; **exercise** for the most robust autophagy stimulus; **caloric restriction by 12-16 hour eating window** for autophagy without pharmacological cost. The framework prefers these.
 **Bottom line:** Rapamycin is appropriate for specific clinical indications (tuberous sclerosis, LAM, transplant, certain cancers, drug-eluting stents). It is not a longevity drug for healthy adults within this framework. The mouse data is a fact about laboratory cancer biology more than a fact about aging; the human data does not support the longevity claim; the side effect profile is real and not eliminated by low-dose intermittent dosing; the framework's response to rapamycin is the case study for applying mechanistic consistency over deference to mainstream longevity culture.
 For users insisting on rapamycin against framework recommendation, harm reduction priorities would include: (1) genotype-aware dose reduction for CYP3A4*22 carriers, (2) intensive lipid monitoring and management, (3) glucose tolerance monitoring (HbA1c, OGTT), (4) protein intake at the upper range (2.0+ g/kg) to partially offset MPS suppression, (5) mandatory resistance training (with awareness that adaptations will be blunted), (6) thyroid panel monitoring, (7) infection vigilance, (8) avoidance of CYP3A4-inhibiting medications and grapefruit, (9) drug holiday around any surgical procedures or wound healing requirements.
 ---